EDIT vs IRD
EDIT: A gene editing pioneer leveraging CRISPR technology to develop in vivo, one-time therapies for serious genetic diseases. IRD: Opus Genetics is a clinical-stage gene therapy company developing a portfolio of durable, one-time treatments for rare inherited retinal diseases.
Side-by-side fundamentals
| Metric | EDIT | IRD | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $2.84 | $4.46 | |
| Market cap | $436M | $371M | |
| Net margin FY2025, SEC XBRL | -395.0% | -349.3% | IRD higher |
| Operating margin FY2025, SEC XBRL | -394.9% | -271.9% | IRD higher |
| ROE FY2025, SEC XBRL | -586.6% | -323.1% | IRD higher |
| ROA FY2025, SEC XBRL | -85.8% | -98.7% | EDIT higher |
| Debt / equity as of 2026-09-03 | 0.53 | 0.07 | IRD lower |
| Revenue growth (YoY) as of 2026-09-03 | +20.8% | -12.2% | EDIT higher |
| Revenue CAGR (3y) SEC XBRL | +27.1% | -29.1% | EDIT higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 2.23 | 0.78 | |
| 1-year return as of 2026-10-08 close | -31.6% | +117.6% | IRD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.